Current Infectious Disease Reports

, Volume 3, Issue 5, pp 469–476 | Cite as

Hepatitis C virus infection in HIV-infected patients

  • Mark S. Sulkowski


The hepatitis C virus (HCV) is a spherical enveloped RNA virus of the Flaviviridae family, classified within the Hepacivirus genus. Since its discovery in 1989, HCV has been recognized as a major cause of chronic hepatitis and hepatic fibrosis that progresses in some patients to cirrhosis and hepatocellular carcinoma. In the United States, approximately 4 million people have been infected with HCV, and 10,000 HCVrelated deaths occur each year. Due to shared routes of transmission, HCV and HIV co-infection are common, affecting approximately one third of all HIV-infected persons in the United States. In addition, HIV co-infection is associated with higher HCV RNA viral load and a more rapid progression of HCV-related liver disease, leading to an increased risk of cirrhosis. HCV infection may also impact the course and management of HIV disease, particularly by increasing the risk of antiretroviral drug-induced hepatotoxicity. Thus, chronic HCV infection acts as an opportunistic disease in HIV-infected persons because the incidence of infection is increased and the natural history of HCV infection is accelerated in co-infected persons. Strategies to prevent primary HCV infection and to modify the progression of HCV-related liver disease are urgently needed among HIV/HCV co-infected individuals.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Centers for Disease Control and Prevention: 1999 USPHS/ IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. USPHS/ IDSA Prevention of Opportunistic Infections Working Group. US Public Health Services/Infectious Diseases Society of America. MMWR 1999, 48:1–82.Google Scholar
  2. 2.
    Choo QL, Richman KH, Han JH, et al.: Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A 1991, 88:2451–2455.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Neumann AU, Lam NP, Dahari H, et al.: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103–107.PubMedCrossRefGoogle Scholar
  4. 4.
    Ogata N, Alter HJ, Miller RH, Purcell RH: Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A 1991, 88:3392–3396.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Abe K, Inchauspe G, Fujisawa K: Genomic characterization and mutation rate of hepatitis C virus isolated from a patient who contracted hepatitis during an epidemic of non-A, non-B hepatitis in Japan. J Gen Virol 1992, 73:2725–2729.PubMedCrossRefGoogle Scholar
  6. 6.
    Stuyver L, Rossau R, Wyseur A, et al.: Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993, 74:1093–1102.PubMedCrossRefGoogle Scholar
  7. 7.
    Donahue JG, Munoz A, Ness PM, et al.: The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992, 327:369–373.PubMedCrossRefGoogle Scholar
  8. 8.
    Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study N Engl J Med. 1996, 334:1685–1690.PubMedCrossRefGoogle Scholar
  9. 9.
    Thomas DL, Vlahov D, Solomon L, et al.: Correlates of hepatitis C virus infections among injection drug users in Baltimore. Medicine 1995, 74:212–220.PubMedCrossRefGoogle Scholar
  10. 10.
    Alter MJ, Hadler SC, Judson FN, et al.: Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990, 264:2231–2235.PubMedCrossRefGoogle Scholar
  11. 11.
    Villano SA, Vlahov D, Nelson KE, et al.: Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997, 35:3274–3277.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Van Ameijden EJ, van den Hoek JA, Mientjes GH, Coutinho RA: A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol 1993, 9:255–262.PubMedCrossRefGoogle Scholar
  13. 13.
    Centers for Disease Control and Prevention: Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998, 47(No. RR-19):1–39.Google Scholar
  14. 14.
    Thomas DL, Zenilman JM, Alter HJ, et al.: Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore: an analysis of 309 sex partnerships. J Infect Dis 1995, 171:768–775.PubMedCrossRefGoogle Scholar
  15. 15.
    Conry-Cantilena C, Vanraden MT, Gibble J, et al.: Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996, 334:1691–1696.PubMedCrossRefGoogle Scholar
  16. 16.
    Everhart JE, Di Bisceglie AM, Murray LM, et al.: Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med 1990, 112:544–545.PubMedCrossRefGoogle Scholar
  17. 17.
    Gordon SC, Patel AH, Kulesza GW, et al.: Lack of evidence for the heterosexual transmission of hepatitis C. Am J Gastroenterol 1992, 87:1849–1851.PubMedGoogle Scholar
  18. 18.
    Brettler DB, Mannucci PM, Gringeri A, et al.: The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study. Blood 1992, 80:540–543.PubMedGoogle Scholar
  19. 19.
    Osmond DH, Padian NS, Sheppard HW, et al.: Risk factors for hepatitis C virus seropositivity in heterosexual couples. JAMA 1993, 269:361–365.PubMedCrossRefGoogle Scholar
  20. 20.
    Thomas DL, Villano SA, Riester KA, et al.: Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. J Infect Dis 1998, 177:1480–1488.PubMedCrossRefGoogle Scholar
  21. 21.
    Zanetti AR, Tanzi E, Paccagnini S, et al.: Mother-to-infant transmission of hepatitis C virus. Lancet 1995, 345:289–291.PubMedCrossRefGoogle Scholar
  22. 22.
    Sulkowski MS, Mast EE, Seeff LB, Thomas DL: Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000, 30(suppl 1):S77–S84.CrossRefGoogle Scholar
  23. 23.
    Makris M, Preston FE, Triger DR, et al.: Hepatitis C antibody and chronic liver disease in haemophilia. Lancet 1990, 335:1117–1119.PubMedCrossRefGoogle Scholar
  24. 24.
    Donahue JG, Nelson KE, Munoz A, et al.: Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol 1991, 134:1206–1211.PubMedGoogle Scholar
  25. 25.
    Alter MJ, Margolis HS, Krawczynski K, et al.: The natural history of community acquired hepatitis C in the United States. N Engl J Med 1992, 327:1899–1905.PubMedCrossRefGoogle Scholar
  26. 26.
    Tong MJ, El-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995, 332:1463–1466.PubMedCrossRefGoogle Scholar
  27. 27.
    Seeff LB, Buskell-Bales ZB, Wright EC, et al.: Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992, 327:1906–1911.PubMedCrossRefGoogle Scholar
  28. 28.
    Kenny-Walsh E: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group N Engl J Med. 1999, 340:1228–1233.PubMedCrossRefGoogle Scholar
  29. 29.
    Fattovich G, Giustina G, Degos F, et al.: Morbidity and mortality in compensated cirrhosis C: a follow-up study of 384 patients. Gastroenterology 1997, 112:463–472.PubMedCrossRefGoogle Scholar
  30. 30.
    Thomas DL, Astemborski J, Rai RM, et al.: The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000, 284:450–456.PubMedCrossRefGoogle Scholar
  31. 31.
    Thomas DL, Astemborski J, Vlahov D, et al.: Determinants of the quantity of hepatitis C virus RNA. J Infect Dis 2000, 181:844–851.PubMedCrossRefGoogle Scholar
  32. 32.
    Thomas DL, Shih JW, Alter HJ, et al.: Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996, 174:690–695.PubMedCrossRefGoogle Scholar
  33. 33.
    Telfer P, Sabin C, Devereux H, et al.: The progression of HCV-associated liver disease in a cohort of hemophiliac patients. Br J Haematol 1994, 87:555–561.PubMedCrossRefGoogle Scholar
  34. 34.
    Sherman KE, O’Brien J, Gutierrez AG, et al.: Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 1993, 31:2679–2682.PubMedCentralPubMedGoogle Scholar
  35. 35.
    Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ: Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Blood 1994, 84:1020–1023.PubMedGoogle Scholar
  36. 36.
    Eyster ME, Diamondstone LS, Lien JM, et al.: Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993, 6:602–610.PubMedGoogle Scholar
  37. 37.
    Darby SC, Ewart DW, Giangrande PL, et al.: Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997, 350:1425–1431.PubMedCrossRefGoogle Scholar
  38. 38.
    Lesens O, Deschenes M, Steben M, et al.: Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999, 179:1254–1258.PubMedCrossRefGoogle Scholar
  39. 39.
    Pol S, Lamorthe B, Thi NT, et al.: Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998, 28:945–950.PubMedCrossRefGoogle Scholar
  40. 40.
    Soriano V, Garcia-Samaniego J, Valencia E, et al.: Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999, 15:1–4.PubMedCrossRefGoogle Scholar
  41. 41.
    Bica I, McGovern B, Dhar R, et al.: Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 32:492–497.PubMedCrossRefGoogle Scholar
  42. 42.
    Dorrucci M, Pezzotti P, Phillips AN, et al.: Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. J Infect Dis 1995, 172:1503–1508.PubMedCrossRefGoogle Scholar
  43. 43.
    Sulkowski MS, Moore RD, Mehta S, Thomas DL: Effect of HCV coinfection on HIV disease progression and survival in HIV-infected adults. Paper presented at 8th Conference on Retroviruses and Opportunistic Infections. February 4–8, 2001. Chicago.Google Scholar
  44. 44.
    Piroth L, Duong M, Quantin C, et al.: Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998, 12:381–388.PubMedCrossRefGoogle Scholar
  45. 45.
    Greub G, Ledergerber B, Battegay M, et al.: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356:1800–1805.PubMedCrossRefGoogle Scholar
  46. 46.
    Brau N, Leaf HL, Wieczorek RL, Margolis DM: Severe hepatitis in three AIDS patients treated with indinavir. Lancet 1997, 349:924–925.PubMedCrossRefGoogle Scholar
  47. 47.
    Arribas JR, Ibanez C, Ruiz-Antoran B, et al.: Acute hepatitis in HIV-infected patients during ritonavir treatment. AIDS 1998, 12:1722–1724.PubMedGoogle Scholar
  48. 48.
    Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V: Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998, 12:1256.PubMedCrossRefGoogle Scholar
  49. 49.
    Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000, 283:74–80.PubMedCrossRefGoogle Scholar
  50. 50.
    den Brinker M, Wit FW, Wertheim-van Dillen PM, et al.: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000, 14:2895–2902.CrossRefGoogle Scholar
  51. 51.
    Ungo JR, Jones D, Ashkin D, et al.: Antituberculosis druginduced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus Am J Respir Crit Care Med. 1998, 157:1871–1876.PubMedCrossRefGoogle Scholar
  52. 52.
    Vento S, Garofano T, Renzini C, et al.: Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998, 12:116–117.PubMedGoogle Scholar
  53. 53.
    John M, Flexman J, French MAH: Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998, 12:2289–2293.PubMedCrossRefGoogle Scholar
  54. 54.
    Zylberberg H, Pialoux G, Carnot F, et al.: Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 1998, 27:1255–1258.PubMedCrossRefGoogle Scholar
  55. 55.
    Thio CL, Nolt KR, Astemborski J, et al.: Screening for hepatitis C virus in human immunodeficiency virus- infected individuals. J Clin Microbiol 2000, 38:575–577.PubMedCentralPubMedGoogle Scholar
  56. 56.
    Chamot E, Hirschel B, Wintsch J, et al.: Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS 1990, 4:1275–1277.PubMedCrossRefGoogle Scholar
  57. 57.
    Mellors JW, Rinaldo CRJ, Gupta P, et al.: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167–1170.PubMedCrossRefGoogle Scholar
  58. 58.
    Centers for Disease Control and Prevention: Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbid Mortal Wkly Rep 1999, 48(RR-12):1–54.Google Scholar
  59. 59.
    Vento S, Garofano T, Renzini C, et al.: Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338:286–290.PubMedCrossRefGoogle Scholar
  60. 60.
    Fanning L, Kenny E, Sheehan M, et al.: Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Hepatology 1999, 29:904–907.PubMedCrossRefGoogle Scholar
  61. 61.
    Perrillo RP: The role of liver biopsy in hepatitis C. Hepatology 1997, 26:57S–61S.PubMedCrossRefGoogle Scholar
  62. 62.
    Poles MA, Dieterich DT, Schwarz ED, et al.: Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV). J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:170–177.PubMedCrossRefGoogle Scholar
  63. 63.
    National Institutes of Health consensus development conference panel statement: Management of hepatitis C. Hepatology 1997, 26:2S–10S.CrossRefGoogle Scholar
  64. 64.
    Soriano V, García-Samaniego J, Bravo R, et al.: Interferon a for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 1996, 23:585–591.PubMedCrossRefGoogle Scholar
  65. 65.
    Soriano V, Bravo R, García-Samaniego J, et al.: Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. AIDS 1997, 11:400–401.PubMedGoogle Scholar
  66. 66.
    Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group: Lancet. 1998, 351:1535–1539.Google Scholar
  67. 67.
    Nishiguchi S, Kuroki T, Nakatani S, et al.: Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet. 1995, 346}:1051–105Google Scholar
  68. 68.
    Nishiguchi S, Shiomi S, Nakatani S, et al.: Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001, 357:196–197.PubMedCrossRefGoogle Scholar
  69. 69.
    Boyer N, Marcellin P, Degott C, et al.: Recombinant interferonalpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 1992, 165:723–726.PubMedCrossRefGoogle Scholar
  70. 70.
    Marriott E, Navas S, Del Romero J, et al.: Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV-positive patients. J Med Virol 1993, 40:107–111.PubMedCrossRefGoogle Scholar
  71. 71.
    Poynard T, Marcellin P, Lee SS, et al.: Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998, 352:1426–1432.PubMedCrossRefGoogle Scholar
  72. 72.
    McHutchison JG, Gordon SC, Schiff ER, et al.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998, 339:1485–1492.PubMedCrossRefGoogle Scholar
  73. 73.
    Landau A, Batisse D, Van Huyen JP, et al.: Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000, 14:839–844.PubMedCrossRefGoogle Scholar
  74. 74.
    Landau A, Batisse D, Piketty C, et al.: Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. AIDS 2000, 14:1857–1858.PubMedCrossRefGoogle Scholar
  75. 75.
    Landau A, Batisse D, Piketty C, Kazatchkine MD: Effect of interferon and ribavirin on HIV viral load. AIDS 2000, 14:96–97.PubMedCrossRefGoogle Scholar
  76. 76.
    Heathcote EJ, Shiffman ML, Cooksley WG, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000, 343:1673–1680.PubMedCrossRefGoogle Scholar
  77. 77.
    Lindsay KL, Trepo C, Heintges T, et al.: A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001, 34:395–403.PubMedCrossRefGoogle Scholar
  78. 78.
    Manns MP, McHutchinson JG, Gordon S, et al.: Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24-week treatment analysis of a multicenter phase III randomized controlled trial [abstract 552]. Hepatology 2000, 32:297A.CrossRefGoogle Scholar
  79. 79.
    Dusheiko G: Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997, 26:112S–121S.PubMedCrossRefGoogle Scholar
  80. 80.
    Deutsch M, Dourakis S, Manesis EK, et al.: Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997, 26:206–210.PubMedCrossRefGoogle Scholar
  81. 81.
    Dieterich DT, et al.: Once-weekly recombinant human erythropoetin (epoetin alfa) facilitates optimal ribavirin (RBV) dosing in hepatitis C viurs (HCV)-infected patients receiving interferon-a-2b combination therapy [abstract 104956]. Gastroenterology 2001, In press.Google Scholar
  82. 82.
    Vogt MW, Hartshorn KL, Furman PA, et al.: Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 198}, 235:1376–1379.CrossRefGoogle Scholar
  83. 83.
    Hoggard PG, Kewn S, Barry MG, et al.: Effects of drugs on 2’,3’-dideoxy-2’,3’-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997, 41:1231–1236.PubMedCentralPubMedGoogle Scholar
  84. 84.
    Baba M, Pauwels R, Balzarini J, et al.: Ribavirin antagonizes inhibitory effects of pyrimidine 2’,3’- dideoxynucleosides but enhances inhibitory effects of purine 2’,3’- dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother 1987, 31:1613–1617.PubMedCentralPubMedCrossRefGoogle Scholar
  85. 85.
    Lafeuillade A, Hittinger G, Chadapaud S: Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001, 357:280–281.PubMedCrossRefGoogle Scholar
  86. 86.
    Japour AJ, Lertora JJ, Meehan PM, et al.: A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13:235–246.PubMedCrossRefGoogle Scholar
  87. 87.
    Zylberberg H, Benhamou Y, Lagneaux JL, et al.: Safety and efficacy of interferon-ribavirin combination therapy in HCV- HIV coinfected subjects: an early report. Gut 2000, 47:694–697.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Mark S. Sulkowski
    • 1
  1. 1.Division of Infectious DiseasesJohns Hopkins Medical InstitutionsBaltimoreUSA

Personalised recommendations